Table 1.
Juvenile-onset SLE patient data
| Demographics | Juvenile-onset SLE patients (n = 30) |
|---|---|
| Number (%) female |
22 (73%) |
| Ethnicity, number |
|
| White British |
22 |
| White other |
1 |
| Asian |
7 |
| Age at sampling, mean (range) years |
12.4 (3.4 – 17.9) |
| Disease duration, mean (range) years |
2.9 (0.01 – 10.2) |
| Biomarker/disease activity parameter, mean (range) |
|
| ESR, mm/hour (normal 2 – 8 mm/hour) |
9.3 (<1 – 60) |
| CRP, mg/litre (normal 0 – 8 mg/litre) |
6.8 (<4 – 78) |
| C3, gm/litre (normal 1.1 – 1.9) |
1.03 (0.4 – 1.37) |
| C4, gm/litre (normal 0.19 – 0.56) |
0.20 (0.08 – 0.46) |
| Anti-dsDNA titre, IU/ml (normal <7) |
7.6 (0 – 96) |
| C-HAQ score, 0–3, mean (range) |
0.32 (0 – 1.5) |
| Physician’s global assessment of disease activity by VAS, mean (range) mm |
20 (0 – 75) |
| SLEDAI score, mean (range) |
4.4 (0 – 17) |
| BILAG-2004 | |
| Number with grade A or grade B |
9 |
| Score, mean (range) |
2.03 (0 – 8) |
| Current medications number of patients |
|
| Hydroxychloroquine |
23 |
| Methotrexate |
3 |
| Azathioprine |
7 |
| Mycophenolate mofetil |
12 |
| Prednisolone |
13 |
| Prednisolone dosage, mean (range) mg/day |
12.2 (1 – 40) |
| Rituximab | 4 |
Data on demographics, biomarker parameters, pBILAG2004 disease activity scores, and current medications in patients with juvenile-onset SLE.
BILAG = British Isles Lupus Assessment Group; SLE = systemic lupus erythematosus; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; anti-dsDNA = anti–double-stranded DNA; C-HAQ = Childhood Health Assessment Questionnaire; VAS = visual analog scale (0–100-mm).